{"claims": [{"text": "In the combined glioma cohort, patients with high MME expression had a median overall survival of 75 months versus 34.9 months for low MME expression.", "quote_or_locator": "Lines 149-153: 'Across all combined glioma histological subtypes, patients with high MME expression (n = 335, events = 96, median survival = 75 months) exhibited significantly prolonged overall survival compared to those with low MME expression (n = 332, events = 143, median survival = 34.9 months, log-rank p < 0.001 and Wilcoxon p < 0.001), with low expression HR = 1.85 (95% CI: 1.43–2.4)'"}, {"text": "Glioblastoma-specific survival analysis showed no statistically significant difference: high MME median 11.3 months, low MME median 14.9 months.", "quote_or_locator": "Lines 154-157: 'glioblastoma-specific survival analysis did not show a statistically significant survival difference between high (n = 76, events = 63, median = 11.3 months) and low (n = 76, events = 55, median = 14.9 months) MME expression groups (HR = 0.81, 95% CI: 0.57–1.17, log-rank p = 0.2652, Wilcoxon p = 0.1132)'"}, {"text": "NEP activity was significantly decreased in the cerebrum (p = 0.0047) and tumor (p = 0.0005) tissues of glioblastoma control group compared to sham control.", "quote_or_locator": "Lines 214-215: 'there was a significant decrease in the NEP activity in the cerebrum (p = 0.0047) and tumor (p = 0.0005) tissues of the glioblastoma control group when compared with the sham control group.'"}, {"text": "NEP protein levels were significantly decreased in cerebrum (p = 0.0007) and tumor (p < 0.0001) tissues of glioblastoma animals compared to normal controls.", "quote_or_locator": "Lines 227-229: 'NEP levels were significantly decreased in the cerebrum and the tumor tissues of the glioblastoma control animals compared with the normal (p = 0.0007 for cerebrum and p < 0.0001 for tumor) and sham control groups'"}, {"text": "PTEN protein levels were significantly decreased in glioblastoma cerebrum and tumor tissues compared to normal and sham controls (p < 0.0001).", "quote_or_locator": "Lines 233-235: 'the PTEN protein levels were significantly decreased in the cerebrum as well as tumour tissues of the glioblastoma rats compared to the normal (p < 0.0001 for cerebrum and tumor) and sham (p = 0.0001 for cerebrum and p = 0.0002 for tumor)) control group'"}, {"text": "AKT protein levels were significantly elevated in glioblastoma control cerebrum (p = 0.033) and tumor (p = 0.035) tissues compared to sham control.", "quote_or_locator": "Lines 239-240: 'The AKT protein levels were significantly elevated in the glioblastoma control cerebrum (p = 0.033) and tumor (p = 0.035) tissues as compared to sham control'"}, {"text": "p53 levels were significantly decreased in glioblastoma-induced cerebrum and tumor tissues compared to normal and sham controls (p < 0.0001).", "quote_or_locator": "Lines 241-242: 'The levels of p53 were also significantly decreased in the glioblastoma-induced cerebrum and tumor tissues compared to normal (p < 0.0001 for cerebrum and tumor) and sham (p < 0.0003 for cerebrum and p = 0.001 for tumor) control groups'"}, {"text": "VEGF-A levels were significantly elevated in glioblastoma cerebrum and tumor tissues compared to normal and sham controls (p = 0.022 for cerebrum, p = 0.0008 for tumor).", "quote_or_locator": "Lines 246-248: 'There was a significant elevation in the levels of VEGF-A in the cerebrum and tumor tissues of the C6 cell-injected animals compared to the normal (p = 0.022 for cerebrum and p = 0.0008 for tumor) and sham (p = 0.009 for cerebrum and p = 0.0004 for tumor) control groups.'"}, {"text": "NEP showed significant positive correlation with PTEN (Spearman's rho = 0.6993, p = 0.0142) and p53 (rho = 0.6014, p = 0.0429).", "quote_or_locator": "Lines 287-288: 'NEP expression showed a significant positive correlation with the tumor suppressor PTEN (rₛ = 0.6993, p = 0.0142) and the cell-cycle regulator p53 (rₛ = 0.6014, p = 0.0429).'"}, {"text": "NEP showed significant negative correlation with VEGF-A (rho = -0.9650, p < 0.0001).", "quote_or_locator": "Lines 289-291: 'prominent and statistically significant inverse correlations were identified between NEP and the oncogenic mediators such as AKT (rₛ = −0.6294, p = 0.0323), VEGF- A (rₛ = −0.9650, p < 0.0001)'"}, {"text": "In human glioblastoma-specific cohort, MME showed significant positive correlation with PTEN (r = +0.19, p = 0.02) and negative correlation with AKT1 (r = -0.21, p = 0.01) and EGFR (r = -0.33, p < 0.001).", "quote_or_locator": "Lines 303-305: 'glioblastoma-specific analysis confirmed a significant positive correlation with PTEN (r = +0.19, p = 0.02), negative correlation with AKT1 (r = -0.21, p = 0.01) and EGFR (r = -0.33, p < 0.001)'"}, {"text": "MME expression was highest in oligodendroglioma (median = 4.66), followed by glioblastoma (median = 3.53) and astrocytoma (median = 3.24).", "quote_or_locator": "Lines 126-129: 'MME mRNA expression analysis across glioma histological subtypes in the TCGA_GBMLGG dataset revealed a distinct variation in MME expression with tumor progression. The MME expression was highest in oligodendroglioma (median = 4.66, mean = 4.70 ± 1.76), followed by glioblastoma (median = 3.53, mean = 3.86 ± 2.19) and astrocytoma (median = 3.24, mean = 3.33 ± 1.76)'"}, {"text": "Brain weight was significantly increased in glioblastoma group (2.037 ± 0.06 g) compared to sham control (1.77 ± 0.03 g) (p < 0.0001).", "quote_or_locator": "Lines 171-172: 'Brain weight was significantly increased in glioblastoma control group (2.037 ± 0.06 g) compared to the sham control (1.77 ± 0.03 g) (p < 0.0001)'"}, {"text": "Tumor weight was 0.24 ± 0.053 g and tumor volume was 410.4 ± 80.57 mm³.", "quote_or_locator": "Lines 175-176: 'In the glioblastoma control group, the tumour weight and volume were found to be 0.24 ± 0.053 g and 410.4 ± 80.57 mm 3 respectively'"}, {"text": "High MME expression was significantly associated with improved disease-free survival (logrank p = 0.0018, HR = 0.67).", "quote_or_locator": "Lines 146-147: 'high MME expression was also significantly associated with improved disease-free survival (DFS) (logrank p = 0.0018, HR = 0.67, p(HR) = 0.0019)'"}], "prompt_version": "p1.0", "verdicts": [{"claim": "In the combined glioma cohort, patients with high MME expression had a median overall survival of 75 months versus 34.9 months for low MME expression.", "verdict": "supported", "evidence": "Lines 149-153: 'Across all combined glioma histological subtypes, patients with high MME expression (n = 335, events = 96, median survival = 75 months) exhibited significantly prolonged overall survival compared to those with low MME expression (n = 332, events = 143, median survival = 34.9 months, log-rank p < 0.001 and Wilcoxon p < 0.001), with low expression HR = 1.85 (95% CI: 1.43–2.4)'", "note": null}, {"claim": "Glioblastoma-specific survival analysis showed no statistically significant difference: high MME median 11.3 months, low MME median 14.9 months.", "verdict": "supported", "evidence": "Lines 154-157: 'glioblastoma-specific survival analysis did not show a statistically significant survival difference between high (n = 76, events = 63, median = 11.3 months) and low (n = 76, events = 55, median = 14.9 months) MME expression groups (HR = 0.81, 95% CI: 0.57–1.17, log-rank p = 0.2652, Wilcoxon p = 0.1132)'", "note": null}, {"claim": "NEP activity was significantly decreased in the cerebrum (p = 0.0047) and tumor (p = 0.0005) tissues of glioblastoma control group compared to sham control.", "verdict": "supported", "evidence": "Lines 214-215: 'there was a significant decrease in the NEP activity in the cerebrum (p = 0.0047) and tumor (p = 0.0005) tissues of the glioblastoma control group when compared with the sham control group.'", "note": null}, {"claim": "NEP protein levels were significantly decreased in cerebrum (p = 0.0007) and tumor (p < 0.0001) tissues of glioblastoma animals compared to normal controls.", "verdict": "supported", "evidence": "Lines 227-229: 'NEP levels were significantly decreased in the cerebrum and the tumor tissues of the glioblastoma control animals compared with the normal (p = 0.0007 for cerebrum and p < 0.0001 for tumor) and sham control groups'", "note": null}, {"claim": "PTEN protein levels were significantly decreased in glioblastoma cerebrum and tumor tissues compared to normal and sham controls (p < 0.0001).", "verdict": "supported", "evidence": "Lines 233-235: 'the PTEN protein levels were significantly decreased in the cerebrum as well as tumour tissues of the glioblastoma rats compared to the normal (p < 0.0001 for cerebrum and tumor) and sham (p = 0.0001 for cerebrum and p = 0.0002 for tumor)) control group'", "note": null}, {"claim": "AKT protein levels were significantly elevated in glioblastoma control cerebrum (p = 0.033) and tumor (p = 0.035) tissues compared to sham control.", "verdict": "supported", "evidence": "Lines 239-240: 'The AKT protein levels were significantly elevated in the glioblastoma control cerebrum (p = 0.033) and tumor (p = 0.035) tissues as compared to sham control'", "note": null}, {"claim": "p53 levels were significantly decreased in glioblastoma-induced cerebrum and tumor tissues compared to normal and sham controls (p < 0.0001).", "verdict": "supported", "evidence": "Lines 241-242: 'The levels of p53 were also significantly decreased in the glioblastoma-induced cerebrum and tumor tissues compared to normal (p < 0.0001 for cerebrum and tumor) and sham (p < 0.0003 for cerebrum and p = 0.001 for tumor) control groups'", "note": null}, {"claim": "VEGF-A levels were significantly elevated in glioblastoma cerebrum and tumor tissues compared to normal and sham controls (p = 0.022 for cerebrum, p = 0.0008 for tumor).", "verdict": "supported", "evidence": "Lines 246-248: 'There was a significant elevation in the levels of VEGF-A in the cerebrum and tumor tissues of the C6 cell-injected animals compared to the normal (p = 0.022 for cerebrum and p = 0.0008 for tumor) and sham (p = 0.009 for cerebrum and p = 0.0004 for tumor) control groups.'", "note": null}, {"claim": "NEP showed significant positive correlation with PTEN (Spearman's rho = 0.6993, p = 0.0142) and p53 (rho = 0.6014, p = 0.0429).", "verdict": "supported", "evidence": "Lines 287-288: 'NEP expression showed a significant positive correlation with the tumor suppressor PTEN (rₛ = 0.6993, p = 0.0142) and the cell-cycle regulator p53 (rₛ = 0.6014, p = 0.0429).'", "note": null}, {"claim": "NEP showed significant negative correlation with VEGF-A (rho = -0.9650, p < 0.0001).", "verdict": "supported", "evidence": "Lines 289-291: 'prominent and statistically significant inverse correlations were identified between NEP and the oncogenic mediators such as AKT (rₛ = −0.6294, p = 0.0323), VEGF- A (rₛ = −0.9650, p < 0.0001)'", "note": null}, {"claim": "In human glioblastoma-specific cohort, MME showed significant positive correlation with PTEN (r = +0.19, p = 0.02) and negative correlation with AKT1 (r = -0.21, p = 0.01) and EGFR (r = -0.33, p < 0.001).", "verdict": "supported", "evidence": "Lines 303-305: 'glioblastoma-specific analysis confirmed a significant positive correlation with PTEN (r = +0.19, p = 0.02), negative correlation with AKT1 (r = -0.21, p = 0.01) and EGFR (r = -0.33, p < 0.001)'", "note": null}, {"claim": "MME expression was highest in oligodendroglioma (median = 4.66), followed by glioblastoma (median = 3.53) and astrocytoma (median = 3.24).", "verdict": "supported", "evidence": "Lines 126-129: 'MME mRNA expression analysis across glioma histological subtypes in the TCGA_GBMLGG dataset revealed a distinct variation in MME expression with tumor progression. The MME expression was highest in oligodendroglioma (median = 4.66, mean = 4.70 ± 1.76), followed by glioblastoma (median = 3.53, mean = 3.86 ± 2.19) and astrocytoma (median = 3.24, mean = 3.33 ± 1.76)'", "note": null}, {"claim": "Brain weight was significantly increased in glioblastoma group (2.037 ± 0.06 g) compared to sham control (1.77 ± 0.03 g) (p < 0.0001).", "verdict": "supported", "evidence": "Lines 171-172: 'Brain weight was significantly increased in glioblastoma control group (2.037 ± 0.06 g) compared to the sham control (1.77 ± 0.03 g) (p < 0.0001)'", "note": null}, {"claim": "Tumor weight was 0.24 ± 0.053 g and tumor volume was 410.4 ± 80.57 mm³.", "verdict": "supported", "evidence": "Lines 175-176: 'In the glioblastoma control group, the tumour weight and volume were found to be 0.24 ± 0.053 g and 410.4 ± 80.57 mm 3 respectively'", "note": null}, {"claim": "High MME expression was significantly associated with improved disease-free survival (logrank p = 0.0018, HR = 0.67).", "verdict": "supported", "evidence": "Lines 146-147: 'high MME expression was also significantly associated with improved disease-free survival (DFS) (logrank p = 0.0018, HR = 0.67, p(HR) = 0.0019)'", "note": null}]}